A Joint Working Project between Boehringer Ingelheim Ltd and NHS Greater Glasgow and Clyde to develop and implement a comprehensive multidisciplinary heart failure service at Glasgow Royal Infirmary and Stobhill Hospital for patients with heart failure and preserved ejection fraction
A Joint Working Project between Boehringer Ingelheim Ltd (BIL) and NHS Greater Glasgow and Clyde (NHSGGC) is aiming to revolutionise treatment and care pathways for patients with heart failure and preserved ejection fraction (HFpEF), through the design and implementation of a new comprehensive multidisciplinary service.
Providing pathways for patients with HFpEF is a challenge for health care providers across the world. There are very few treatments available to improve the care of this patient cohort who have a high burden of symptoms and high rates of death and hospitalisation.
The Scottish Government Heart disease improvement plan (priority 5) aims to improve the journey of care for patients with heart failure by developing a whole system approach to the delivery of care1 and through the creation of this multidisciplinary heart failure service, BIL and NHSGGC hope the project can be used as a blueprint for the UK, and other healthcare systems around the world.2
The project aims to operationalise in January 2023 and is anticipated to run for 36 months.
Boehringer Ingelheim Ltd is pleased to collaborate with NHS Greater Glasgow and Clyde to design and deliver an innovative model of care which provides equitable access to care for patients with HFpEF.
References
1. Priorities - Heart Disease Improvement Plan - gov.scot (www.gov.scot)
2. Personal communication – Professor Jackie Taylor, Consultant Physician in Geriatric Medicine, NHS Scotland
NP-GB-103401 V2 March 2023